Conversely, the U.S. Food & Drug Administration (FDA)-approved AD drug; donepezil, has been selected to compare the its efficacy with vitexin in acting as antagonist against TLR4/MD-2 complex of microglia. The gene discussed is LY96; the disease is Alzheimer disease.